Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 6:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 605 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Functional Clear all
Completed Phase 1 Interventional

Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis

NCT00003368
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
45
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Oct 26, 2026, 6:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function

NCT06962774
View directory record Official record
Conditions
Renal Impairment
Interventions
ESK-001
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
4
States / cities
Miami, Florida • Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 26, 2026, 6:47 AM EDT
Terminated Not applicable Interventional

OMT of Somatic Dysfunction and Chronic Low Back Pain in Patients With Type 2 Diabetes Mellitus

NCT02054650
View directory record Official record
Conditions
Chronic Low Back Pain, Type 2 Diabetes Mellitus
Interventions
Osteopathic Manual Treatment (OMT), Sham OMT
Other
Lead sponsor
University of North Texas Health Science Center
Other
Eligibility
18 Years to 79 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 26, 2026, 6:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Brain Imaging Study of Adults With Autism Spectrum Disorders

NCT01093768
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Oxytocin, Vasopressin
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 40 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 26, 2026, 6:47 AM EDT
Terminated Phase 1 Interventional

A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease

NCT01839526
View directory record Official record
Conditions
Fabry Disease
Interventions
Iohexol
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
5 Years to 25 Years · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
La Jolla, California • Decatur, Georgia • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 26, 2026, 6:47 AM EDT
Terminated Not applicable Interventional Results available

Interventions Made to Preserve Cognitive Function

NCT03616535
View directory record Official record
Conditions
ESRD
Interventions
Cognitive training, Exercise training, Combined cognitive and exercise training
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 26, 2026, 6:47 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Influence of Osmotic Stimulation of Vasopressin on Autonomic Function

NCT04233606
View directory record Official record
Conditions
Water Stress, Body Water Dehydration
Interventions
Hypertonic Saline, Normal Saline
Other
Lead sponsor
University of North Carolina, Greensboro
Other
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 26, 2026, 6:47 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Quest to Analyze One Thousand Humans Meditating

NCT06583395
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma, Atrial Fibrillation, Cancer Brain, Cancer, Breast, Cancer Colon, Cancer, Lung, Cancer, Ovarian, Cancer Prostate, Cancer Skin, Throat Cancer, Lymphoma, Cancer, Thyroid, Cancer, Other, Cerebral Palsy, Chronic Fatigue Syndrome, Cluster Headache, Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Diseases, Crohn Disease, Deafness, Depression, Diabetes, Eczema, Epilepsy, Fibroids, Fibromyalgia, Heart Failure, Hypertension, Hyperthyroidism, Hypothyroidism, Irritable Bowel Syndrome (IBS), Infertility, Lyme Disease, Macular Degeneration, Migraine, Multiple Allergies, Multiple Sclerosis, Osteoarthritis, Osteoporosis, Ovarian Cysts, Parkinson Disease, Phantom Limb Pain, Psoriasis, Post Traumatic Stress Disorder (PTSD), Rheumatoid Arthritis, Sjogrens Disease, Spinal Cord Injury, Spinal Stenosis, Stroke, Tension Headache, Tinnitus, Ulcerative Colitis
Interventions
Advanced multi-component meditation practice
Behavioral
Lead sponsor
Tobias Moeller-Bertram
Industry
Eligibility
21 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Palm Desert, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 26, 2026, 6:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Salivary Phosphorus and Level of Kidney Function

NCT01311973
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
Denver Nephrologists, P.C.
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 26, 2026, 6:47 AM EDT
Recruiting Not applicable Interventional

Accelerated Age-related Cognitive Decline: Impact of Exercise on Executive Function and Neuroplasticity

NCT05655325
View directory record Official record
Conditions
Mild Cognitive Impairment, Chronic Kidney Diseases
Interventions
Home-based walking exercise, Attention control
Behavioral · Other
Lead sponsor
Columbia University
Other
Eligibility
55 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 26, 2026, 6:47 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control

NCT03242252
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3
Interventions
Placebo, Sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
51
States / cities
Birmingham, Alabama • Guntersville, Alabama • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 26, 2026, 6:47 AM EDT
Recruiting No phase listed Observational

Drug Interaction Potential of Pro-Inflammatory Conditions

NCT07360938
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, End Stage Renal Disease, Irritable Bowel Syndrome
Interventions
None (Observational)
Other
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 99 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 26, 2026, 6:47 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

NCT06307652
View directory record Official record
Conditions
Heart Failure and Impaired Kidney Function
Interventions
balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
3,850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
166
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 26, 2026, 6:47 AM EDT
Terminated Not applicable Interventional Results available

The Effect of Fenoldopam in Solitary Partial Nephrectomy Surgery

NCT00743106
View directory record Official record
Conditions
Partial Nephrectomy
Interventions
Fenoldopam, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 26, 2026, 6:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal Function

NCT02400307
View directory record Official record
Conditions
HIV
Interventions
Bictegravir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 79 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
5
States / cities
DeLand, Florida • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2019 · Synced Oct 26, 2026, 6:47 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function

NCT07853131
View directory record Official record
Conditions
Renal Impairment, Healthy Volunteers
Interventions
rilzabrutinib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 26, 2026, 6:47 AM EDT
Completed No phase listed Observational

Intraoperative Transesophageal Echocardiography Assessment of Portal Vein Flow and Renal Resistive Index As a Predictor of Acute Kidney Injury After Cardiac Surgery: A Prospective Observational Study

NCT04112953
View directory record Official record
Conditions
AKI
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 26, 2026, 6:47 AM EDT
Completed No phase listed Observational

Comparison of Markers of Kidney Function

NCT01403766
View directory record Official record
Conditions
Chronic Kidney Disease, Renal Insufficiency
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
1 Year to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 26, 2026, 6:47 AM EDT
Completed Phase 1 Interventional

A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

NCT01904214
View directory record Official record
Conditions
Renal Impairment
Interventions
BAF312
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 26, 2026, 6:47 AM EDT
Completed Early Phase 1 Interventional

Statins for Pulmonary and Cardiac Complications of Chronic HIV - Coordinating Center

NCT01881971
View directory record Official record
Conditions
HIV Seropositivity
Interventions
Placebo, Rouvastatin calcium
Drug
Lead sponsor
Alison Morris
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 26, 2026, 6:47 AM EDT
Completed Phase 2 Interventional

An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.

NCT00235300
View directory record Official record
Conditions
Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection, Induction Therapy
Interventions
Thymoglobulin [Anti-thymocyte Globulin (rabbit)], Simulect (basliximab)
Biological · Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 26, 2026, 6:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function

NCT01730469
View directory record Official record
Conditions
Fabry Disease
Interventions
AT1001 150 mg
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
4
States / cities
Costa Mesa, California • Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 26, 2026, 6:47 AM EDT
Terminated Phase 4 Interventional Results available

A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease

NCT03119662
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Visipaque, Placebos
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
17
States / cities
Birmingham, Alabama • Mesa, Arizona • Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 26, 2026, 6:47 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Potassium, Hydration, Cardiovascular, and Kidney Study (PHACKs)

NCT06062017
View directory record Official record
Conditions
Blood Pressure, Hydration, Vascular Disease Risk
Interventions
Water and Potassium supplementation
Dietary Supplement
Lead sponsor
Auburn University
Other
Eligibility
18 Years to 30 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 26, 2026, 6:47 AM EDT